61257-02-1
Chemical Structure
Mycaminosyltylonolide
- CAS No.: 61257-02-1
- Formula:C31H51NO10
- Molecular Weight:597.74
IUPAC Name: 2-((4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-(((2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-16-ethyl-4-hydroxy-15-(hydroxymethyl)-5,9,13-trimethyl-2,10-dioxooxacyclohexadeca-11,13-dien-7-yl)acetaldehyde
InChIKey: WGUJDBLMJBJUQU-VKRLOHBMSA-N
SMILES: O=CC[C@@H](C[C@H](C(/C=C/C(C)=C/[C@@H]([C@H](OC(C[C@H]([C@@H]1C)O)=O)CC)CO)=O)C)[C@@H]1O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O
Biological Activity: Mycaminosyltylonolide is a potent antibiotic. Mycaminosyltylonolide shows antibacterial activity. Mycaminosyltylonolide inhibits luciferase synthesis[1][2].
| Cat. No. | 상품명 | Purity | 제품 설명 | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mycaminosyltylonolide | 95.0% | Mycaminosyltylonolide is a potent antibiotic. Mycaminosyltylonolide shows antibacterial activity. Mycaminosyltylonolide inhibits luciferase synthesis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mycaminosyltylonolide (Standard) | Deoxynivalenol (Standard) is the analytical standard of Deoxynivalenol. This product is intended for research and analytical applications. Deoxynivalenol, an orally active mycotoxin of the trichothecenes family, crosses the intestinal mucosa by a paracellular pathway through the tight junctions. The Deoxynivalenol transport is not affected by P-glycoprotein (PgP) or multidrug resistance-associated proteins (MRPs) inhibitors. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Shishkina A, et al. Conjugates of amino acids and peptides with 5-o-mycaminosyltylonolide and their interaction with the ribosomal exit tunnel. Bioconjug Chem. 2013 Nov 20;24(11):1861-9. [Content Brief]
- [2]. Sugawara A, et al. 5-O-Mycaminosyltylonolide antibacterial derivatives: design, synthesis and bioactivity. J Antibiot (Tokyo). 2017 Jul;70(8):878-887. [Content Brief]
